SCHEMBL2487253

SCHEMBL2487253

COc1ccc(C(=O)NC(C)(C)C(=O)Nc2nc(-c3ccccc3)c(Cc3ccccc3)s2)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLTP P55058 6/20 0.50
DGAT1 O75907 2/20 0.46
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 3/20 0.45
LMNA P02545 2/20 0.45
RORC P51449 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
FOXO1 Q12778 1/20 0.43
CFTR P13569 1/20 0.43
TRPV4 Q9HBA0 2/20 0.42
MEN1 O00255 2/20 0.42
NPC1 O15118 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
KCNH2 Q12809 1/20 0.41
CETP P11597 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2487506 0.92 PLTP (0.52) PLTPDGAT1KMT2ARORCTP53
SCHEMBL2318313 0.90 PLTP (0.49) PLTPDGAT1KMT2AALDH1A1LMNA
SCHEMBL2491014 0.86 ADORA1 (0.55) PLTPDGAT1KMT2AALDH1A1RORC
SCHEMBL2360230 0.86 DGAT1 (0.59) PLTPDGAT1KMT2AALDH1A1LMNA
SCHEMBL2490614 0.85 NPC1 (0.51) PLTPDGAT1KMT2ALMNARORC
SCHEMBL2489832 0.85 TRPV4 (0.57) PLTPDGAT1ALDH1A1RORCMAPT
SCHEMBL13531700 0.84 PLTP (0.55) PLTPDGAT1KMT2AALDH1A1RORC
SCHEMBL2491127 0.84 NPC1 (0.48) PLTPDGAT1KMT2AALDH1A1LMNA
SCHEMBL2313671 0.83 PLTP (0.51) PLTPDGAT1KMT2ARORCMAPT
SCHEMBL2490496 0.82 PLTP (0.52) PLTPDGAT1KMT2AALDH1A1RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 PLTP 575/4885DGAT1 1/4885KMT2A 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.